TMCnet News

Baxalta Files Registration Statement for Secondary Offering of Common Stock in Connection with the Exercise of Demand Registration Rights by Baxter
[September 01, 2015]

Baxalta Files Registration Statement for Secondary Offering of Common Stock in Connection with the Exercise of Demand Registration Rights by Baxter


Baxalta Incorporated (NYSE:BXLT) announced it has filed a Registration Statement on Form S-1 with the Securities and Exchange Commission (SEC (News - Alert)) today in connection with the proposed secondary offering of up to $1.45 billion of common stock of the company currently held by Baxter International Inc. (NYSE:BAX). J.P. Morgan Securities LLC is acting as the sole underwriter for the offering.

The proposed offering is consistent with the previously disclosed plan of Baxter to engage in certain debt-for-equity exchanges to dispose of its retained stake in Baxalta in a tax-free manner within the 18-month period following Baxalta's separation from Baxter. Baxalta is not selling any shares in the offering and will not receive any proceeds from the offering.

When available, copies of thepreliminary prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling (866) 803-9204.



A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these shares in any state in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any state.


About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical company developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Launched in 2015 following its separation from Baxter, Baxalta's therapies are available in more than 100 countries. Baxalta is headquartered in Northern Illinois.


[ Back To TMCnet.com's Homepage ]